Marissa S. Mattar

3.3k citations

22 papers · 666 indexed · 1 hit paper · h-index 12

Cancer Research top 10%
- Cancer Genomics and Diagnostics 6
Oncology top 10%
- HER2/EGFR in Cancer Research 4
- Cancer Cells and Metastasis 3
Immunology
Pulmonary and Respiratory Medicine top 10%
- Lung Cancer Treatments and Mutations 9
- Sarcoma Diagnosis and Treatment 3
Hepatology
Molecular Biology
- PI3K/AKT/mTOR signaling in cancer 3
- Glycosylation and Glycoproteins Research 2
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 3

Co-authors: Elisa de Stanchina Charles M. Rudin Natasha Rekhtman Marc Ladanyi Inna Khodos Romel Somwar Dana Pe’er Joan Massagué
Cited by: Cancer Research Oncology Immunology
Journals: Nature Medicine (1 paper)Nature Communications (1 paper)Journal of Clinical Oncology (3 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Marissa S. Mattar

21 papers receiving 651 citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Marissa S. Mattar

Since Specialization

Citations

This map shows the geographic impact of Marissa S. Mattar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marissa S. Mattar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marissa S. Mattar more than expected).

Fields of papers citing papers by Marissa S. Mattar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marissa S. Mattar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marissa S. Mattar. The network helps show where Marissa S. Mattar may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Marissa S. Mattar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Marissa S. Mattar Line = papers co-authored together Marissa S. Mattar links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor Clinical Cancer Research ·Tom Zhang,Christopher A. Febres‐Aldana,Zebing Liu,Jenna-Marie Dix,Ryan Cheng,Raymond G. Dematteo,Allan J.W. Lui,Inna Khodos,Leo Gili,Marissa S. Mattar,Jeanine Lisanti,Charlene Kwong,Irina Linkov,Murray J. Tipping,Elisa de Stanchina,Igor Odintsov,Marc Ladanyi,Romel Somwar	2024	6
2	Prospective Clinical Genomic Profiling of Ewing Sarcoma: ERF and FGFR1 Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance JCO Precision Oncology ·Koichi Ogura,Arielle Elkrief,Anita S. Bowman,Richard P. Koche,Elisa de Stanchina,Ryma Benayed,Audrey Mauguen,Marissa S. Mattar,Inna Khodos,Paul A. Meyers,John H. Healey,William D. Tap,Meera Hameed,Ahmet Zehir,Neerav Shukla,Charles L. Sawyers,Rohit Bose,Emily K. Slotkin,Marc Ladanyi	2022	6
3	MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression npj Precision Oncology ·Dylan Farnsworth,Yusuke Inoue,Fraser Johnson,Georgia de Rappard-Yuswack,Daniel Lu,Rocky Shi,Lok In Josephine,Marissa S. Mattar,Romel Somwar,Marc Ladanyi,Arun M. Unni,William W. Lockwood	2022	7
4	Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer Nature Communications ·Patrícia M. R. Pereira,Komal Mandleywala,Sébastien Monette,Melissa Lumish,Kathryn M. Tully,Sandeep Surendra Panikar,Mike Cornejo,Audrey Mauguen,Ashwin Ragupathi,Nai Keltee,Marissa S. Mattar,Yelena Y. Janjigian,Jason S. Lewis	2022	27
5	The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions Clinical Cancer Research ·Igor Odintsov,Allan J.W. Lui,Whitney J. Sisso,Eric Gladstone,Zebing Liu,Lukas Delasos,Renate I. Kurth,Exequiel M. Sisso,Morana Vojnic,Inna Khodos,Marissa S. Mattar,Elisa de Stanchina,Shawn M. Leland,Marc Ladanyi,Romel Somwar	2021	31
6	Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers Journal of Thoracic Oncology ·Igor Odintsov,Marissa S. Mattar,Allan J.W. Lui,Michael Offin,Christopher Kurzatkowski,Lukas Delasos,Inna Khodos,Marina Asher,Robert Michael Daly,Natasha Rekhtman,Elisa de Stanchina,Gopinath Ganji,Marc Ladanyi,Romel Somwar	2021	21
7	Abstract P233: TAS0953/HM06 is effective in preclinical models of diverse tumor types driven by RET alterations Molecular Cancer Therapeutics ·Igor Odintsov,Renate I. Kurth,Kota Ishizawa,Lukas Delasos,Allan J.W. Lui,Inna Khodos,Connor J. Hagen,Qing Chang,Marissa S. Mattar,Morana Vojnic,Siddharth Kunte,Annalisa Bonifacio,Claudio Giuliano,Elisa de Stanchina,Emily H. Cheng,Emanuela Lovati,Marc Ladanyi,Romel Somwar	2021	5
8	Abstract 956: The HER2×HER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions Cancer Research ·Igor Odintsov,Inna Khodos,Madelyn Espinosa‐Cotton,Allan J.W. Lui,Marissa S. Mattar,Alison M. Schram,Ron C.J. Schackmann,Jeroen Lammerts van Bueren,Cecile Geuijen,Elisa de Stanchina,Marc Ladanyi,Romel Somwar	2021	1
9	Signatures of plasticity and immunosuppression in a single-cell atlas of human small cell lung cancer. Journal of Clinical Oncology ·Joseph M. Chan,Àlvaro Quintanal-Villalonga,Vianne R. Gao,Viola Allaj,Ignas Masilionis,Ojasvi Chaudhary,Jacklynn V. Egger,Andrew Chow,Thomas Walle,Marissa S. Mattar,Michael Offin,W. Victoria Lai,Matthew J. Bott,Travis Hollman,Tal Nawy,Linas Mažutis,Triparna Sen,Dana Pe’er,Charles M. Rudin	2021	3
10	Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor Clinical Cancer Research ·Koichi Ogura,Romel Somwar,Julija Hmeljak,Heather Magnan,Ryma Benayed,Amir Momeni Boroujeni,Anita S. Bowman,Marissa S. Mattar,Inna Khodos,Elisa de Stanchina,Achim A. Jungbluth,Marina Asher,Igor Odintsov,Alifiani B. Hartono,Michael P. LaQuaglia,Emily K. Slotkin,Christine A. Pratilas,Sean Bong Lee,Lee Spraggon,Marc Ladanyi	2020	24
11	Regenerative lineages and immune-mediated pruning in lung cancer metastasisbreakdown → Nature Medicine ·Ashley M. Laughney,Jing Hu,Nathaniel R. Campbell,Samuel F. Bakhoum,Manu Setty,Vincent‐Philippe Lavallée,Yubin Xie,Ignas Masilionis,Ambrose Carr,Sanjay Kottapalli,Viola Allaj,Marissa S. Mattar,Natasha Rekhtman,João B. Xavier,Linas Mažutis,John T. Poirier,Charles M. Rudin,Dana Pe’er,Joan Massagué	2020	251
12	Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer Cancer Immunology Immunotherapy ·Tao Dao,Martin G. Klatt,Tatyana Korontsvit,Sung Soo Mun,Sean Guzman,Marissa S. Mattar,Oliver Zivanovic,Chrisann Kyi,Nicholas D. Socci,Roisin E. O’Cearbhaill,David A. Scheinberg	2020	8
13	NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors Communications Biology ·Romel Somwar,Nicolle E. Hofmann,Bryan D. Smith,Igor Odintsov,Morana Vojnic,Irina Linkov,Ashley Tam,Inna Khodos,Marissa S. Mattar,Elisa de Stanchina,Daniel L. Flynn,Marc Ladanyi,Alexander Drilon,Ujwal Shinde,Monika A. Davare	2020	41
14	Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma Clinical Lung Cancer ·Marissa S. Mattar,Jason C. Chang,Ryma Benayed,Darragh Halpenny,Astin S. Powers,David E. Kleiner,Alexander Drilon,Mark G. Kris	2019	1
15	Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer Clinical Cancer Research ·Ken Suzawa,Michael Offin,Daniel Lu,Christopher Kurzatkowski,Morana Vojnic,Roger S. Smith,Joshua K. Sabari,Huichun Tai,Marissa S. Mattar,Inna Khodos,Elisa de Stanchina,Charles M. Rudin,Mark G. Kris,Maria E. Arcila,William W. Lockwood,Alexander Drilon,Marc Ladanyi,Romel Somwar	2018	83
16	Establishing and Maintaining an Extensive Library of Patient-Derived Xenograft Models Frontiers in Oncology ·Marissa S. Mattar,Craig McCarthy,Amanda Kulick,Besnik Qeriqi,Sean Guzman,Elisa de Stanchina	2018	35
17	Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy OncoImmunology ·Rikke Holmgaard,Alexandra Brachfeld,Billel Gasmi,David R. Jones,Marissa S. Mattar,Thompson N. Doman,Mary Y. Murphy,David Schaer,Jedd D. Wolchok,Taha Merghoub	2016	55
18	MDM2 amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with advanced RET-rearranged lung cancers. Journal of Clinical Oncology ·Romel Somwar,Roger S. Smith,Takuo Hayashi,Kota Ishizawa,Alexandra Snyder,Inna Khodos,Marissa S. Mattar,Jie He,Sohail Balasubramanian,Phil Stephens,Doron Lipson,Elisa de Stanchina,Monika A. Davare,Vincent A. Miller,Gregory J. Riely,Charles M. Rudin,Mark G. Kris,Emily H. Cheng,Marc Ladanyi,Alexander Drilon	2016	19
19	Non-haematological traits associated with congenital dyserythropoietic anaemia type 1: a new entity emerging Clinical Dysmorphology ·Mohamed Sabry,Mohammed Zaki,Sadika Al Awadi,Q. Al Saleh,Marissa S. Mattar	1997	11
20	Degenerative changes and detection of plasminogen in fetal membranes that rupture prematurely BJOG An International Journal of Obstetrics & Gynaecology ·D.M. Jenkins,Maeve O'Neill,Marissa S. Mattar,VENIETIA M. FRANCE,Bae‐Li Hsi,W. Pagé Faulk	1983	29

About Marissa S. Mattar

Marissa S. Mattar is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research, having authored 22 papers that have together received 666 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (9 papers), Cancer Genomics and Diagnostics (6 papers), HER2/EGFR in Cancer Research (4 papers), PI3K/AKT/mTOR signaling in cancer (3 papers), Cancer Cells and Metastasis (3 papers), Sarcoma Diagnosis and Treatment (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Glycosylation and Glycoproteins Research (2 papers). The work is most often cited by research in Cancer Research (175 citations), Oncology (313 citations) and Immunology (153 citations). Marissa S. Mattar has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Elisa de Stanchina, Charles M. Rudin, Natasha Rekhtman, Marc Ladanyi, Inna Khodos, Romel Somwar, Dana Pe’er, Joan Massagué, Viola Allaj and Jing Hu. Their work appears in journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact